The landscape of Alzheimer’s diagnostics is undergoing a significant transformation. Recent clinical studies and reports from mid-2026 confirm the increasing reliability of blood biomarkers in identifying Alzheimer-related pathologies. These blood tests enable a more precise and earlier diagnosis compared to traditional methods, suggesting that blood tests could play a central role in clinical routines and […]
August 3, 2026Author(s)Yogesh Shah, MD, MPH, FAAFP Dr. Yogesh Shah, MD, reviews the evidence supporting P-tau217 as a reliable rule-in biomarker for Alzheimer’s pathology and discusses how clinicians can incorporate blood-based testing into patient evaluation.As blood-based biomarkers move closer to routine clinical use, demonstrating agreement with established diagnostic standards remains essential. For Alzheimer disease (AD), […]
Residents of the College Park Towers Senior Apartments in Orlando gathered Wednesday for Bilingual Activ8 Your Brain Bingo, an event designed to promote brain health through fun, interactive activities. The nonprofit Global Alzheimer’s Platform Foundation partnered with Conquest Research to offer brain health education and free cognitive screenings. Engage speaks with participants and organizers about simple habits that can help […]
24 Jul 2026 Part 2 of 2No, they are not Optimus Jr, Megatron’s clones, or any other new, amyloid-shattering members of the Tron family franchise of transformer robots, though perhaps Roche does not mind if you think so for a moment. Rather, the TRONTIER twins are currently enrolling Phase 3 trials for early AD, and […]
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer’s dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals — with accuracy matching or exceeding the ADAS-Cog, MoCA and MMSE benchmarks. LONDON, July 15, 2026 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global […]
Symbol Swap matched or exceeded ADAS-Cog, MoCA, and MMSE across three independent studiesBy Henry BakerPublished: Jul 15 2026, 3:39 PM EDT On the final day of the world’s largest dementia research conference, a startup presented data Wednesday suggesting that a two-minute tablet task can do what a trained clinician typically takes 10 to 45 minutes to […]
July 1, 2026 The Nguoit Viet News wrote an article in Vietnamese on how hundreds of residents attended a free health fair at St. Columban Church. The Mobile Research Unit was at the event and had a record of 55 screenings while sharing the importance of brain health. To read the article in Vietnamese from […]
By:Ingrid Johansen, Date: July 7, 2026 A significant global research initiative is underway to develop a convenient blood test for diagnosing Alzheimer’s disease. The study focuses on three specific proteins linked to the condition, aiming to compare the efficacy of the test with current brain scans. If successful, this new test could offer a simpler […]
John Dwyer, the President of the Global Alzheimer’s Platform Foundation (GAP) joins TrialSiteNews to discuss a collaboration and partnership with Circular Genomics. The partnership will analyze blood test samples to investigate the potential for circular RNA biomarkers to assist in the diagnosis & treatment of Alzheimer’s Disease. Topics covered: Press Release: https://globalalzplatform.org/2026/05…
Story by Amy Scherzer, Bay Correspondent Tearful yet joyful, the annual Inspire, Imagine & Hope Gala honored Tampa neurologist Dr. Susan Steen for her 40-plus years advancing brain health education and leading clinical trials for Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Gala co-chairs Lyle Fogarty and Dr. Shannon Moroney shared the personal impact of […]
TrialSite Staff | Making Biomedical Research Evidence Accessible to All May. 18, 2026, 2:30 p.m. The global battle against Alzheimer’s disease may increasingly hinge on one critical factor: detecting the disease earlier, faster, and more accurately before irreversible neurological decline takes hold. This week, the Global Alzheimer’s Platform Foundation (GAP) announced the continued expansion of its Bio-Hermes-002 […]
The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of dementia… The Global Alzheimer’s Platform Foundation expands the Bio-Hermes-002 study, incorporating Sanofi and other industry leaders, to refine blood and digital biomarkers for more inclusive, earlier diagnosis of […]
Could Alzheimer’s disease one day be detected with a simple blood test instead of expensive brain scans? In this episode of the TrialSite News Farago Podcast, we speak with John Dwyer, President and CEO of the Global Alzheimer’s Platform Foundation (GAP), about the Bio-Hermes-002 study and the future of Alzheimer’s detection. The conversation explores how […]
Representatives from Butler Hospital’s Memory and Aging Program and the Global Alzheimer’s Platform recently visited the Swansea Council on Aging to discuss normal memory changes with age and new research in Alzheimer’s prevention. The session also encouraged residents to engage with the Acti-v8 initiative and join a prevention registry. This content is adapted from materials provided by Swansea Council On Aging This article includes […]
Houston, Texas (April 15, 2026) – Re:Cognition Health, a global leader in new treatments for Alzheimer’s Disease, is delivering an international clinical trial to evaluate whether a simple finger-prick blood test can revolutionize how Alzheimer’s disease is diagnosed. Compared with the current invasive and expensive diagnostic methods, this approach could provide a scalable solution for […]
Apr 17, 2026 | Dementias & Alzheimer’s, Immunoassay | The study will analyze three key proteins to determine if blood-based biomarkers can provide an earlier and more accessible diagnostic method. Re:Cognition Health is delivering an international clinical trial to evaluate whether a finger-prick blood test can improve how Alzheimer’s disease is diagnosed. Compared with current invasive and expensive diagnostic methods, this approach aims […]
Siemens Healthineers has become a licensed partner in the Bio-Hermes-002 Alzheimer’s study. Erin Brady April 13, 2026 The Global Alzheimer’s Platform Foundation (GAP) has announced that Siemens Healthineers has joined the Bio-Hermes-002 study alongside several other industry leaders. Siemens is now a licensed partner of the study, aiming to enhance Alzheimer’s diagnostics. Specifically, Siemens Healthineers will work to “change the paradigm […]
The Global Alzheimer’s Platform Foundation (GAP) has announced a strategic collaboration with Siemens Healthineers for the Bio-Hermes-002 study, an observational platform designed to evaluate biomarkers for Alzheimer’s disease and related dementias. The study compares blood-based and digital biomarkers across a wide range of cognitive conditions, alongside MRI and PET imaging data, to generate insights that […]
By Knowridge -March 25, 2026Alzheimer’s disease is one of the most common causes of memory loss in older adults. It slowly affects the brain, making it harder for people to remember things, think clearly, and carry out daily activities. As the global population ages, more and more families are facing the challenges of this condition. Because of […]
Alzheimer’s disease is one of the most feared illnesses of aging. It slowly damages memory, thinking, and behavior, and over time it makes it difficult for people to carry out everyday tasks. For decades, scientists have focused mainly on one key feature of the disease: sticky clumps of a protein called amyloid that build up […]
Long before Alzheimer’s disease became a global crisis, it was already shaping quiet, devastating stories inside individual families. Science was fragmented. Treatments were elusive. And for decades, progress moved more slowly than anyone anticipated. For entrepreneurs working in healthcare, the challenge was not just scientific. It was structural. How do you build companies that can […]
Las Vegas is set to host a significant gathering of Alzheimer’s and Parkinson’s disease research leaders this week, as the Global Alzheimer’s Platform Foundation (GAP) convenes its annual conference from February 25th through February 27th at the Red Rock Casino Resort & Spa. The event will bring together nearly 250 representatives from over 100 clinical […]
by Chloe KoastTue, February 24, 2026 at 9:36 AM From February 25th through the 27th the Global Alzheimer’s Platform Foundation will meet up at the Red Rock Casino Resort & Spa. More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer’s. This includes announcing a new […]
The disease currently is diagnosed using expensive scans and lumbar punctures or spinal taps. February 18, 2026 By: Michael Barbella Managing Editor Alzheimer’s disease detection could be quite literally at our fingertips. A major international research project is underway at the U.K. Dementia Research Institute (DRI) to test whether a finger prick-style blood test could be […]